Phase I evaluation of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) and dianhydrogalactitol (DAG; NSC-132313) in patients with advanced neoplastic diseases.
D001853:Bone Marrow / Q000187:drug effects; D002330:Carmustine / Q000008:administration & dosage* / Q000633:toxicity; D003961:Dianhydrogalactitol / Q000008:administration & dosage* / Q000633:toxicity; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D013402:Sugar Alcohols / Q000008:administration & dosage*
D013402:Sugar Alcohols; D003961:Dianhydrogalactitol; D002330:Carmustine